LabGenomics Co., Ltd. (KOSDAQ:084650)

Market Cap	177.06B
Revenue (ttm)	87.90B
Net Income (ttm)	-20.16B
Shares Out	74.24M
EPS (ttm)	-271.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	653,985
Average Volume	1,474,853
Open	2,440.00
Previous Close	2,440.00
Day's Range	2,390.00 - 2,450.00
52-Week Range	1,991.00 - 5,420.00
Beta	-0.31
RSI	49.95
Earnings Date	Aug 14, 2025

About Revance Therapeutics

LabGenomics Co., Ltd. engages in the research and development of biotechnology products in South Korea. It is also involved in the sale of diagnostic devices. The company was founded in 2002 and is based in Seongnam-si, South Korea.

• Industry: Commercial Physical and Biological Research
• Founded: 2002
• Employees: 163
• Stock Exchange: KOSDAQ
• Ticker Symbol: 084650

Financial Performance

In 2024, LabGenomics's revenue was 85.90 billion, an increase of 20.85% compared to the previous year's 71.08 billion. Losses were -23.80 billion, 409.1% more than in 2023.